Ñî¹óåú´«Ã½Ò•îl

The U.S. Food and Drug Administration declined to approve expanded use of Acadia Pharmaceuticals Inc's antipsychotic drug for treating psychosis related to Alzheimer's disease, the company said on Thursday. (8/5)

With the tumultuous rollout of Aduhelm behind them, partners Biogen and Eisai have the rare opportunity for a do-over, with all-important data on their next Alzheimer’s disease therapy expected next month. (Feuerstein and Garde, 8/10)

Aclinical trial run by Amgen that combined its KRAS-targeting cancer drug called Lumakras with other immunotherapies caused serious liver side effects — forcing lung cancer patients to abandon treatment and leading to substantially lower tumor response rates. (Feuerstein, 8/7)

Amgen Inc on Thursday agreed to buy ChemoCentryx Inc (CCXI.O) for $3.7 billion to gain access to a potential blockbuster treatment for inflammatory disorders and beat quarterly revenue estimates on demand for its bone disease drug. (Mishra, 8/4)

Karuna Therapeutics said Monday that a novel combination pill reduced psychosis and related symptoms experienced by patients with schizophrenia, achieving the main goals of a late-stage clinical trial. (Feuerstein, 8/8)

AstraZeneca said on Thursday its drug Lynparza, developed with U.S.-based Merck & Co was approved by the European Union as an adjuvant treatment for patients with a form of a genetically mutated early-stage breast cancer. (8/4)

A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according to findings published Monday in the European Heart Journal. (Cueto, 8/8)

The $5.4 billion acquisition of Global Blood Therapeutics by Pfizer was sealed with a phone call and a commitment to reach patients with sickle cell disease wherever in the world they live. (Feuerstein, 8/9)